Exelixis, the cancer drug developer, appears to have paid the price for its plans to raise funds from sale of 20 million shares and $225 million in debt. The South San Francisco-based company's stock price dropped 12% on Monday and was down nearly 4% on Tuesday at 11:54 a.m. ET.
Newly hatched Atterocor has gained the wherewithal to push ahead with a lead drug for adrenal cancer. The Ann Arbor, MI-based biotech snapped up $16 million from Frazier Healthcare and early-stage specialist 5AM Ventures, the company announced this morning.
Bristol-Myers Squibb swung for the fences and whiffed, and the company's major miss provides a victory to Onyx Pharmaceuticals, the white-hot provider of Nexavar.
A toxic plant native to the Mediterranean gave investigators the pieces they needed to craft a "molecular grenade" capable of attacking tumors in mice. And they say it holds out the prospect of a new therapy that might one day address a broad range of cancers.
In a series of rapid-fire press releases over the past 18 hours, cancer drug upstart Verastem vaulted to the threshold of Phase II with an in-licensing deal with Pfizer, announced a development pact with Eisai and ran through a series of highlights for its R&D day review.
In a bid to dig deeper in the battle against liver cancer, scientists in Virginia have developed the first mouse model that shows some of the things a specific gene appears to be responsible for in advancing the deadly disease.
Researchers have opened a new front in the war on deadly skin cancer. With their groundbreaking finding that the interleukin-9 molecule stymies melanoma growth in mice, the researchers have uncovered a potential new way to harness immune activity to combat cancer.
ADC Therapeutics (ADCT) and Cancer Research UK's Cancer Research Technology (CRT) group have taken up arms together to develop a slate of antibody-drug conjugates for attacking tumors.
The Cancer and Prevention Research Institute of Texas, launched in 2007, may soon start spending more of its $3 billion in taxpayer-funded grant money on private startups and less on academic research.
FierceBiotech virtually relocated the whole team to Boston this year, where we had a great turnout for our executive breakfast exploring how virtual drug development strategies are influencing everyone in the industry, big and small. We also collected a slideshow of photographs of the people attending BIO this year.